Conventional contrast-enhanced magnetic resonance imaging is typically performed with extracellular gadolinium chelates, which is often limited in patients with CKD owing to the risk of nephrogenic systemic fibrosis. Ferumoxytol, a novel contrast medium, can be used as an "off-label" contrast agent for magnetic resonance imaging. During the last decade, ferumoxytol has gained appeal as an MRI contrast agent in patients with estimated glomerular filtration rates \<30mL/min and there are reports in the literature for its safe use and utility in both adult and pediatric patients with CKD. The study is designed to evaluate the diagnostic performance of ferumoxytol-enhanced magnetic resonance imaging in patients suspected of renal artery stenosis, investigate the correlation between renal cortical T2\*(T2\*=1/R2\*) and renal function, and develop an automatic algorithms for renal vessel segmentation.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
the degree of renal artery stenosis
Timeframe: baseline and after intervention
quantitative cortical T2* value
Timeframe: baseline and after intervention
change of hemoglobin level
Timeframe: baseline,72 hours,30 days,3 months
serum creatinine
Timeframe: baseline,72 hours,30 days,3 months
Urine routine
Timeframe: baseline,72 hours,30 days,3 months
24-hour urine biochemistry
Timeframe: baseline,72 hours,30 days,3 months
Retinol binding protein
Timeframe: baseline,72 hours,30 days,3 months
Neutrophil gelatinase-associated lipocalin
Timeframe: baseline,72 hours,30 days,3 months
Serum iron
Timeframe: baseline,72 hours,30 days,3 months
Ferritin
Timeframe: baseline,72 hours,30 days,3 months
Transferrin
Timeframe: baseline,72 hours,30 days,3 months
serum cystatin C
Timeframe: baseline,72 hours,30 days,3 months